ESMO20: abemaciclib in combination with endocrine therapy shows promise for breast cancer

Written by Rachel Jenkins, Future Science Group


Data presented at the Presidential Symposium at the ESMO Virtual Congress 2020 has demonstrated that abemaciclib, also known as Verzenio, in combination with standard adjuvant endocrine therapy (ET) can significantly decrease the risk of breast cancer recurrence by 25% compared with standard adjuvant ET alone for people with HR+, HER- high-risk early breast cancer. The results, also published in the Journal of Clinical Oncology, are from a preplanned interim analysis of the Phase III monarchE trial evaluating the effects of 2 years of abemaciclib treatment added to ET among people whose breast cancer is at high risk of recurrence. Lead...

To view this content, please register now for access

It's completely free